Loading
Co-developed CancerSEEK, the blood test that showed multi-cancer early detection is possible, and ran the first prospective screening study of it.
Nickolas Papadopoulos co-led with Bert Vogelstein and Kenneth Kinzler the development of CancerSEEK, the blood test combining ctDNA mutations and protein markers that detected eight cancer types, and the DETECT-A study, the first prospective trial to show a blood test can find cancers in asymptomatic women and lead to curative surgery. He co-founded Thrive (now part of Exact Sciences) and discovered mismatch repair genes with the Hopkins group.
A blood test can find early, treatable cancers in people who feel well, including cancers for which no screening exists. It is not a replacement for mammography or colonoscopy but a possible addition. Larger randomised trials are needed to show benefit outweighs harm.
The proof of principle for multi-cancer blood tests that include pancreas; the sensitivity figures come from known cancers, not from screening.
It quantifies how little DNA an operable pancreatic cancer sheds and why every serious early detection panel pairs DNA with proteins.
It set the frame that every later landscape paper filled in: pancreatic cancer is a disease of a few pathways broken by many different genes, so drugs must aim at pathways or their dependencies rather than one rare mutation.
Shares Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tags early-detection, mced.
Shares Multi-cancer early detection (MCED) and the tags early-detection, mced.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag liquid-biopsy.
Shares Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms.
Shares Detection and localization of surgically resectable cancers with a multi-analyte blood test, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center.
Shares Multi-cancer early detection (MCED), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Liquid biopsy (ctDNA).
Shares Liquid biopsy (ctDNA) and the tag liquid-biopsy.
Shares Multi-cancer early detection (MCED) and the tag early-detection.